New breast cancer drug challenger aims to match standard treatment
NCT ID NCT04514419
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This study tests whether a new drug called HS627 works as well as the approved drug pertuzumab when both are given with trastuzumab and chemotherapy before surgery for early or locally advanced HER2-positive breast cancer. About 408 participants will receive either HS627 or pertuzumab for four cycles. The main goal is to see if the cancer disappears completely in the breast tissue at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266000, China
Conditions
Explore the condition pages connected to this study.